Skip to main content
SpringerLink
Log in

Interdisziplinäre Therapie von Knochenmetastasen

  • Chapter
Fortbildung Osteologie 4

Part of the book series: Fortbildung Osteologie ((FORTOSTEO,volume 4))

  • 794 Accesses

Zusammenfassung

Die Prognose von Patienten mit Knochenmetastasen ist individuell abhängig vom zugrunde liegenden Primarius. In den letzten Jahren ist die Lebenserwartung von Patienten durch die Fortschritte in der systemischen Therapie (Chemotherapie, Immuntherapie, antihormonelle Therapie) und der radioonkologischen Interventionen deutlich verbessert worden. Dieses Kapitel stellt die Anwendung der gängigen Osteologika bei ossärer Metastasierung, die Radionuklidtherapie und chirurgisch-orthopädische Möglichkeiten vor sowie die ethischen Aspekte, die beim Scoring von Patienten mit Knochenmetastasen zu berücksichtigen sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 49.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

Literatur zu Abschn. 3.1

  • Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, Rubens RD (1998) Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16: 3890–9

    Article  CAS  PubMed Central  Google Scholar 

  • Body JJ, Casimiro S, Costa L (2015) Targeting bone metastases in prostate cancer: improving clinical outcome. Nat Rev Urol. 12: 340–56

    Article  PubMed Central  Google Scholar 

  • Buckwalter JA, Brandser EA (1997) Metastatic disease of the skeleton. Am Fam Physician 55: 1761–8

    Google Scholar 

  • Carter JA, Joshi AD, Kaura S, Botteman MF (2012) Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours. Pharmacoeconomics 30: 373–86

    Article  PubMed Central  Google Scholar 

  • Gartrell BA, Saad F (2014) Managing bone metastases and reducing skeletal related events in prostate cancer. Nat Rev Clin Oncol 11: 335–45

    Article  CAS  PubMed Central  Google Scholar 

  • Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI (2013) Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst 105: 654–63

    Article  CAS  PubMed Central  Google Scholar 

  • Hofbauer LC, Rachner TD, Coleman RE, Jakob F (2014) Endocrine aspects of bone metastases. Lancet Diabetes Endocrinol 2: 500–12

    Article  CAS  Google Scholar 

  • Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16: 2038–44

    Article  CAS  PubMed Central  Google Scholar 

  • Hussein O, Tiedemann K, Murshed M, Komarova SV (2012) Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases. Cancer Lett 314: 176–84

    Article  CAS  PubMed Central  Google Scholar 

  • Lipton A, Fizazi K, Stopeck AT, Henry DH, Smith MR, Shore N, Martin M, Vadhan-Raj S, Brown JE, Richardson GE, Saad F, Yardley DA, Zhou K, Balakumaran A, Braun A (2016) Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer 53: 75–83.

    Article  CAS  PubMed Central  Google Scholar 

  • McGreevy C, Williams D (2011) Safety of drugs used in the treatment of osteoporosis. Ther Adv Drug Saf 2: 159–72

    Article  PubMed Central  Google Scholar 

  • Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449–56

    Google Scholar 

  • Parker C, Finkelstein SE, Michalski JM, O’Sullivan JM, Bruland Ø, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R, Seger MA, Bottomley D (2016) Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial. Eur Urol Jun 22. pii: S0302–2838 (16)30272-X. doi: 10.1016/j.eururo.2016.06.002. [Epub ahead of print]

    Article  CAS  PubMed Central  Google Scholar 

  • Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzén L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369: 213–23

    Article  CAS  PubMed Central  Google Scholar 

  • Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98: 1735–44

    Article  CAS  Google Scholar 

  • Sartor O, Coleman R , Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O’Bryan-Tear CG, Shan M, Bruland ØS, Parker C (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 15: 738–46

    Article  CAS  PubMed Central  Google Scholar 

  • Yong M, Jensen AÖ, Jacobsen JB, Nørgaard M, Fryzek JP, Sørensen HT (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007). Breast Cancer Res Treat 129: 495–503

    Article  PubMed Central  Google Scholar 

Literatur zu Abschn. 3.2

  • Baczyk M, Czepczynski R, Milecki P, Pisarek M, Oleksa R, Sowinski J (2007) 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun 28 (4): 245–250. doi: 10.1097/MNM.0b013e32805b72a0

    Article  Google Scholar 

  • Brahme A (2011) Accurate description of the cell survival and biological effect at low and high doses and LET’s. J Radiat Res 52 (4): 389–407. doi: 10.1269/jrr.10129

    Article  CAS  PubMed Central  Google Scholar 

  • Bruland OS, Nilsson S, Fisher DR, Larsen RH (2006) High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 12 (20 Pt 2): 6250s-6257s. doi: 10.1158/1078–0432.CCR-06–0841

  • Bryan JN, Bommarito D, Kim DY, Berent LM, Bryan ME, Lattimer JC, Henry CJ, Engelbrecht H, Ketring A, Cutler C (2009) Comparison of systemic toxicities of 177Lu-DOTMP and 153Sm-EDTMP administered intravenously at equivalent skeletal doses to normal dogs. J Nucl Med Technol 37 (1): 45–52. doi: 10.2967/jnmt.108.054700

    Article  PubMed Central  Google Scholar 

  • Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31 (5): 578–583

    Article  CAS  PubMed Central  Google Scholar 

  • Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, Group EGW (2012) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 Suppl 7: vii11–19. doi: 10.1093/annonc/mds232

    Article  PubMed Central  Google Scholar 

  • Chow E, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, Brundage MD, Nabid A, Tissing-Tan CJ, Oei B, Babington S, Demas WF, Wilson CF, Meyer RM, Chen BE, Wong RK (2014) Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol 15 (2): 164–171. doi: 10.1016/S1470–2045 (13)70556–4

  • Christensen MH, Petersen LJ (2012) Radionuclide treatment of painful bone metastases in patients with breast cancer: a systematic review. Cancer Treat Rev 38 (2): 164–171. doi: 10.1016/j.ctrv.2011.05.008

    Article  CAS  PubMed Central  Google Scholar 

  • Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M, Flamen P (2014) A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res Treat 145 (2): 411–418. doi: 10.1007/s10549–014–2939–1

  • Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, Livingston RB, Gordon EE, Chapman CR, Appelbaum FR (1993) Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 34 (11): 1839–1844

    Google Scholar 

  • Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A (2001) A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 28 (7): 788–798

    Article  CAS  PubMed Central  Google Scholar 

  • Dickie GJ, Macfarlane D (1999) Strontium and samarium therapy for bone metastases from prostate carcinoma. Australas Radiol 43 (4): 476–479

    Article  CAS  PubMed Central  Google Scholar 

  • ESMO – European Society for Medical Oncology (2017) EMA issues warning about use of radium-223 dichloride in combination with abiraterone acetate and prednisone or prednisolone. [http://www.esmo.org/Oncology-News/EMA-Issues-Warning-About-Use-of-Radium-223-Dichloride-in-Combination-With-Abiraterone-Acetate-and-Prednisone- or-Prednisolone]

  • Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A (2009) Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 27 (15): 2429–2435. doi: 10.1200/JCO.2008.18.9811

    Article  CAS  PubMed Central  Google Scholar 

  • Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C (2014) Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 15 (12): 1397–1406. doi: 10.1016/S1470–2045 (14)70474–7

  • Kraeber-Bodere F, Campion L, Rousseau C, Bourdin S, Chatal JF, Resche I (2000) Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 27 (10): 1487–1493

    Article  PubMed Central  Google Scholar 

  • Deutsche Gesellschaft für Nuklearmedizin e.V. (Hrsg) 2014) Leitlinien der Deutschen Gesellschaft für Nuklearmedizin e.V. (DGN): Radionuklidtherapie bei schmerzhaften Knochenmetastasen. http://www.nuklearmedizin.de/leistungen/leitlinien/html/radionuk_ther.php?navId=53

  • Liepe K, Franke WG, Kropp J, Koch R, Runge R, Hliscs R (2000) Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases. Nuklearmedizin Nucl Med 39 (6): 146–151

    Article  PubMed Central  Google Scholar 

  • Liepe K, Kotzerke J (2007) A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 28 (8): 623–630. doi: 10.1097/MNM.0b013e32825a6adc

    Article  CAS  PubMed Central  Google Scholar 

  • Mathe D, Balogh L, Polyak A, Kiraly R, Marian T, Pawlak D, Zaknun JJ, Pillai MR, Janoki GA (2010) Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent. Nucl Med Biol 37 (2): 215–226. doi: 10.1016/j.nucmedbio.2009.09.004

    Article  PubMed Central  Google Scholar 

  • Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O’Donoghue J, Larson S, Scher HI (2009) Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 27 (15): 2436–2442. doi: 10.1200/JCO.2008.20.4164

    Article  CAS  PubMed Central  Google Scholar 

  • Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A (2011) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59 (4): 572–583. doi: 10.1016/j.eururo.2011.01.025

    Article  PubMed Central  Google Scholar 

  • Nair N (1999) Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. J Nucl Med 40 (2): 256–261

    Google Scholar 

  • Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS (2005) First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11 (12): 4451–4459. doi: 10.1158/1078–0432.CCR-04–2244

  • Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, Grunwald F, Knapp FF, Jr., Biersack HJ (2000) Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med 27 (2): 123–130

    Google Scholar 

  • Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzen L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O, Investigators A (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. NEJM 369 (3): 213–223. doi: 10.1056/NEJMoa1213755

    Article  CAS  PubMed Central  Google Scholar 

  • Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D (1997) A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 33 (10): 1583–1591

    Article  CAS  PubMed Central  Google Scholar 

  • Ricci S, Boni G, Pastina I, Genovesi D, Cianci C, Chiacchio S, Orlandini C, Grosso M, Alsharif A, Chioni A, Di Donato S, Francesca F, Selli C, Rubello D, Mariani G (2007) Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imag 34 (7): 1023–1030. doi: 10.1007/s00259–006–0343–8

  • Ritter MA, Cleaver JE, Tobias CA (1977) High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature (London) 266 (5603): 653–655

    Article  CAS  PubMed Central  Google Scholar 

  • Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O’Bryan-Tear CG, Shan M, Bruland OS, Parker C (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 15 (7): 738–746. doi: 10.1016/S1470–2045 (14)70183–4

  • Schoeneich G, Muller SC, Palmedo H (1998) [Indications for nuclear medicine therapy in advanced prostate carcinoma]. Urologe Ausg A 37 (2): 162–166

    Article  CAS  PubMed Central  Google Scholar 

  • Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S, Maini CL (2001) Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat 66 (2): 101–109

    Article  CAS  PubMed Central  Google Scholar 

  • Serafini AN (2000) Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer 88 (12 Suppl): 2934–2939

    Article  CAS  PubMed Central  Google Scholar 

  • Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA (1998) Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16 (4): 1574–1581

    Article  CAS  PubMed Central  Google Scholar 

  • Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, Brill AB, Song H, Howell RW, Akabani G, Committee SM, Bolch WE, Brill AB, Fisher DR, Howell RW, Meredith RF, Sgouros G, Wessels BW, Zanzonico PB (2010) MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 51 (2): 311–328. doi: 10.2967/jnumed.108.058651

    Article  CAS  PubMed Central  Google Scholar 

  • Shinto AS, Shibu D, Kamaleshwaran KK, Das T, Chakraborty S, Banerjee S, Thirumalaisamy P, Das P, Veersekar G (2014) (1) (7) (7)Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases. J Nucl Med Technol 42 (1): 55–61. doi: 10.2967/jnmt.113.132266

    Article  PubMed Central  Google Scholar 

  • Silberstein EB (1993) The treatment of painful osseous metastases with phosphorus-32-labeled phosphates. Semin Oncol 20 (3 Suppl 2): 10–21

    Google Scholar 

  • Sinzinger H, Palumbo B, Ozker K (2011) The Vienna protocol and perspectives in radionuclide therapy. Q J Nucl Med Mol Imag 55 (4): 420–430

    Google Scholar 

  • Todenhöfer T, Müller M (2014) Radionuklidtherapie im Behandlungskonzept von Knochenmetastasen. Osteologie 23: 269–274

    Article  Google Scholar 

  • Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ (2001) Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357 (9253): 336–341. doi: 10.1016/S0140–6736(00)03639–4

  • von Moos R, Body JJ, Egerdie B et al. (2013) Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer 21: 3497

    Article  PubMed Central  Google Scholar 

  • Wenzl T, Wilkens JJ (2011) Theoretical analysis of the dose dependence of the oxygen enhancement ratio and its relevance for clinical applications. Radiat Oncol 6: 171. doi: 10.1186/1748–717X-6–171

  • Yuan J, Liu C, Liu X, Wang Y, Kuai D, Zhang G, Zaknun JJ (2013) Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study. Clin Nucl Med 38 (2): 88–92. doi: 10.1097/RLU.0b013e318279bf4d

    Article  PubMed Central  Google Scholar 

Literatur zu Abschn. 3.3

  • Boriani S, Weinstein JN, Biagini R (1997) Primary bone tumors of the spine. Terminology and surgical staging. Spine 22: 1036–1044

    Article  CAS  Google Scholar 

  • Deramond H, Depriester C, Toussaint P, Galibert P (1997) Percutaneous vertebroplasty. Semin Musculoskelet Radiol 285–296

    Article  PubMed Central  Google Scholar 

  • Haentjens P, Casteleyn PP, Opdecam P (1993) Evaluation of impending fractures and indications for prophylactic fixation of metastases in long bones: review of the literature. Acta Orthop Belg 59(suppl 1): 6–11

    Google Scholar 

  • Harrington KD (1986) Impending pathologic fractures from metastatic malignancy: evaluation and management. Instructional Course Lectures 35: 357–381

    Google Scholar 

  • Hillen TJ, Anchala P, Friedman MV, Jennings JW (2014) Treatment of Metastatic Posterior Vertebral Body Osseous Tumors by Using a Targeted Bipolar Radiofrequency Ablation Device: Technical Note. Radiology 273 (1): 261–267. doi: http://dx.doi.org/10.1148/ radiol.14131664

  • Hipp JA, Springfields DS, Hayes WC (1995) Predicting pathologic fracture risk in the management of metastatic bone defects. Clin Orthop 312: 120–35

    Google Scholar 

  • Hong J, Cabe G, Tedrow J, Hipp J, Snyder B (2004) Failure of trabecular bone with simulated lytic defects can be predicted non-invasively by structural analysis. J Orthop Res 22: 479–486

    Article  PubMed Central  Google Scholar 

  • Kurth AA, Eberhardt C (2014) Die chirurgisch-orthopädische Behandlung von Knochenmetastasen. Osteologie 23: 281–286

    Article  Google Scholar 

  • Mankin HJ, Mankin CJ, Simon MA (1996) The hazards of the biopsy, revisited. Members of the musculoskeletal tumor society. J Bone Joint Surg Am 78: 656–663

    Google Scholar 

  • Mirels H (1989) Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res 249: 256–64

    Google Scholar 

  • Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2 (8): 584–593

    Article  CAS  PubMed Central  Google Scholar 

  • Papathanassiou ZG, Petsas T, Papachristou D, Megas P (2011) Radiofrequency ablation of osteoid osteomas: five years experience. Acta Orthopaed Belg 77: 827–33

    Google Scholar 

  • Patchell RA, Tibbs PA, Regine WF et al. (2005) Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366 (9486): 643–648

    Article  Google Scholar 

  • Phadke DM, Lucas DR, Madan S (2001) Fine-needle aspiration biopsy of vertebral and intervertebral disc lesions: Specimen adequacy, diagnostic utility, and pitfalls. Arch Pathol Lab Med 125: 1463–1468

    Google Scholar 

  • Piccioli A, Ventura A, Maccauro G, Spinelli MS, Del Bravo V, Rosa MA (2011) Local adjuvants in surgical management of bone metastases. Int J Immunopathol Pharmacol 24 (1) (Suppl 2): 129–32

    Article  CAS  PubMed Central  Google Scholar 

  • Proschek D, Kurth A, Proschek P, Vogl TJ, Mack MG (2009) Prospective pilot-study of combined bipolar radiofrequency ablation and application of bone cement in bone metastases. Anticancer Research 29: 2787–92

    Google Scholar 

  • Proschek D, Tonak M, Mack M, Kurth AA (2012) Radiofrequency ablation in experimental bone metastases using a controlled and navigated ablation device. J Bone Oncol 9, 1: 63–66, http://dx.doi.org/10.1016/j.jbo.2012.07.001

    Article  CAS  PubMed Central  Google Scholar 

  • Tancioni F, Lorenzetti MA, Navarria P et al. (2011) Percutaneous vertebral augmentation in metastatic disease: state of the art. J Support Oncol 9 (1): 4–10

    Article  PubMed Central  Google Scholar 

  • Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T (2001) Surgical strategy for spinal metastases. Spine 26: 298–306

    Article  CAS  Google Scholar 

  • Wedin R (2001) Surgical treatment for pathological fracture. Acta Orthop Scand Suppl 72: 1.29

    Google Scholar 

Literatur zu Abschn. 3.4

  • Akashe-Böhme F, Böhme G (2005) Mit Krankheit leben. Von der Kunst, mit Schmerz und Leid umzugehen. Beck´sche Reihe. Beck, München

    Google Scholar 

  • Holle R (1995) Methoden zur Konstruktion und Evaluierung klinischer Scores. Inst. für Med. Biometrie u. Informatik, Abt. Med. Biometrie, Univ Heidelberg

    Google Scholar 

  • Krainer L, Heintel P (2010) Prozessethik. Zur Organisation ethischer Entscheidungsprozesse. Verlag für Sozialwissenschaften, Wiesbaden

    Book  Google Scholar 

  • Schmidt MC (2008) Griff nach dem Ich? Ethische Kriterien für die medizinische Intervention in das menschliche Gehirn. De Gruyter, Berlin

    Google Scholar 

  • von der Höh NH, Gulow J, Tschöke SK et al (2013) Prognostische Scores bei Wirbelsäulenmetastasen. Orthopäde 42: 725–733

    Article  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Orthopädie, Unfallchirurgie und Plastische Chirurgie, Universitätsklinikum Leipzig, Leipzig, Deutschland

    Dr. med. Johannes Fakler

  2. Klinik für Urologie Tübingen, Eberhard-Karls-Universität Tübingen, Tübingen, Deutschland

    Dr. med. Tilman Todenhöfer

  3. Heidelberg, Deutschland

    Mark Müller

  4. Abteilung für Orthopädie und Unfallchirurgie, Asklepios Klinik Birkenwerder, Birkenwerder, Deutschland

    Prof. Dr. med. Andreas A. Kurth

  5. Orthopädie und Unfallchirurgie, Asklepios Klinik, Langen, Deutschland

    Priv.-Doz. Dr. med. Christian Eberhardt

  6. Krankenhaus- und Altenheimseelsorger, Evangelisches Krankenhaus, Bergisch Gladbach, Deutschland

    Pastor Dr. Rainer Fischer

Authors
  1. Dr. med. Johannes Fakler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. med. Tilman Todenhöfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. Dr. med. Andreas A. Kurth
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Priv.-Doz. Dr. med. Christian Eberhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pastor Dr. Rainer Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dr. Becker Rhein-Sieg-Klinik, Nümbrecht, Deutschland

    Klaus M. Peters

  2. Rheinische Klinik für Orthopädie Viersen, Viersen, Deutschland

    Dietmar Pierre König

  3. Universität Leipzig, Leipzig, Deutschland

    Andreas Roth

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fakler, J., Todenhöfer, T., Müller, M., Kurth, A.A., Eberhardt, C., Fischer, R. (2018). Interdisziplinäre Therapie von Knochenmetastasen. In: Peters, K.M., König, D.P., Roth, A. (eds) Fortbildung Osteologie 4. Fortbildung Osteologie, vol 4. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-52748-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-52748-1_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-52747-4

  • Online ISBN: 978-3-662-52748-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation